Judge postpones OxyContin-maker Purdue Pharma's sentencing to let opioid victims attend in person

A judge on Tuesday delayed the criminal sentencing of OxyContin maker Purdue Pharma in order to allow victims to attend the court proceeding in person.U.S. District Judge Madeline Cox Arleo was originally planning to hand down the sentence Tuesday during a court proceeding conducted only by videoconferencing. But she said she changed her mind after seeing some victims of the opioid crisis protesting outside her courthouse in Newark, New Jersey. She said they should be allowed to attend in person, too, and moved the hearing to next Tuesday.When it happens, Arleo is expected to order the company to forfeit $225 million to the Justice Department, clearing the way for the company to finalize a settlement of nearly all of the thousands of lawsuits it faces over its role in the opioid crisis.The penalty was agreed to in a 2020 pact to resolve federal civil and criminal probes it was facing. If the judge signs off, other penalties will not be collected in return for Purdue settling the other lawsuits.After years of legal twists and turns, the settlement was approved by another judge last year and could take effect as soon as a week after the sentence is delivered. It requires members of the Sackler family who own the company to pay up to $7 billion to state, local and Native American tribal governments, some individual victims and others.Here’s a look at the situation.The sentence was years in the makingPurdue pleaded guilty to three federal criminal charges in November 2020.The Stamford, Connecticut-based company admitted that it did not have an effective program to keep its powerful prescription painkillers from being diverted to the black market, even though it told the U.S. Drug Enforcement Administration that it did.It also admitted that it paid doctors through a speakers program to prescribe the drugs and paid an electronic medical records company to send doctors information on patients that encouraged more opioid prescriptions.While Purdue produced only a fraction of the opioid pills that flooded the market in the 2000s, advocates have long seen aggressive sales of OxyContin as one of the touchstones of the crisis. At a 1996 event to rally Purdue’s sales force, Richard Sackler, then a top Purdue executive and later president of the company, called for a “blizzard of prescriptions.”While Purdue is expected to pay $225 million, the government agreed in the plea deal not to collect $5.3 billion in criminal forfeitures and fines and $2.8 billion in civil liabilities. Instead, portions of that money are considered part of the broader settlement—and the federal government will receive a small slice of that.Up to $7 billion from Sackler family membersThe broader settlement calls for members of the Sackler family who own the company to contribute up to $7 billion over 15 years. Most of the money is to go to government entities to use to fight the opioid crisis.It’s among the largest in a series of settlements by drugmakers, wholesalers and pharmacies in recent years—and the only major one that includes payments for some individual victims or their survivors.Together, the settlements are worth more than $50 billion, and most of the money is to be used to address the overdose epidemic.Under the Purdue deal, members of the Sackler family would be shielded from lawsuits over opioids from those who agree to the payments.Purdue itself would cease to exist and be replaced by a new company, Knoa Pharma, which would operate for the public benefit and have a board appointed by the states.The reorganization is considered one of the most complicated ever. By the end of last year, Purdue had paid law firms and other professionals working on all sides of the case more than $1 billion, according to a court filing.The sentencing doesn’t include the company’s ownersMembers of the Sackler family have long been cast as villains in the opioid crisis, seeking to increase profits even as it became clear people were becoming addicted to OxyContin and overdosing.But no members of the family were charged.Family members received $10.7 billion in payments from Purdue from 2008 to 2018—with nearly half of it used to pay taxes on behalf of Purdue. They have not been paid by the company since 2018—and the last of them left Purdue’s board in 2019.Under the settlement, they would not object if their names are removed from museums and other institutions they’ve supported—something that’s already been happening.Some victims are pushing for prosecutionsMore than 54,000 people with personal injury claims against Purdue voted to accept the settlement, and 218 voted against it.Still, some victims and their family members have been pushing back for years, asserting that the settlement and the guilty plea stop short of justice for victims of a crisis that has been linked to 900,000 deaths in the U.S. since 1999.Tuesday’s sentencing is one more chance for them to make that case to a judge.Susan Ousterman’s son, Tyler Cordiero, died at age 24 in 2020 after overdosing on a mixture that included fentanyl after years of using heroin and other opioids. She organized others who lost loved ones to deliver victim impact statements to the court ahead of the sentencing.She said the aim was to persuade the judge to reject the plea deal and for the U.S. Justice Department to pursue criminal charges against individuals, including Sackler family members.“It shouldn’t be going to states and municipalities,” said Ousterman, noting some governments have not yet used the funds they’re received and others have used it in ways not closely linked to fighting the drug crisis. “They’re not using that money effectively.”

Judge postpones OxyContin-maker Purdue Pharma's sentencing to let opioid victims attend in person

Register for free access or login.

Related Topics